Overview

Dexmedetomidine in Modifying Immune Paralysis In Patient With Septic Shock

Status:
Unknown status
Trial end date:
2020-03-20
Target enrollment:
Participant gender:
Summary
in this study the investigators aim to assess the role of using dexmedetomidine as sedative in septic shock patients in comparison with midazolam. The investigators aim to assess the effect on immune response and inflammatory mediators and effect on vasopressors.
Phase:
Phase 2
Details
Lead Sponsor:
Kasr El Aini Hospital
Treatments:
Dexmedetomidine
Midazolam